These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26476229)

  • 1. Biologic Therapy for Psoriatic Arthritis.
    Mease PJ
    Rheum Dis Clin North Am; 2015 Nov; 41(4):723-38. PubMed ID: 26476229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to biological therapy for psoriatic arthritis.
    Boyd T; Kavanaugh A
    Expert Opin Biol Ther; 2016; 16(2):173-86. PubMed ID: 26572089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.
    Caso F; Lubrano E; Del Puente A; Caso P; Peluso R; Foglia F; Benigno C; Girolimetto N; Bottiglieri P; Scarpa R; Costa L
    Expert Rev Clin Immunol; 2016; 12(3):315-31. PubMed ID: 26558483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.
    Raychaudhuri SP; Wilken R; Sukhov AC; Raychaudhuri SK; Maverakis E
    J Autoimmun; 2017 Jan; 76():21-37. PubMed ID: 27836567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
    Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
    J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Treatment Concepts in Psoriatic Arthritis.
    Boyd T; Kavanaugh A
    Rheum Dis Clin North Am; 2015 Nov; 41(4):739-54. PubMed ID: 26476230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies.
    Walsh JA; Cai Q; Lin I; Fitzgerald T; Pericone CD; Chakravarty SD
    Curr Med Res Opin; 2020 Jul; 36(7):1245-1252. PubMed ID: 32271088
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
    Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination systemic therapies in psoriatic arthritis.
    Daly M; Alikhan A; Armstrong AW
    J Dermatolog Treat; 2011 Oct; 22(5):276-84. PubMed ID: 20666676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic advances reveal new targets in psoriasis and psoriatic arthritis.
    Mortezavi M; Ritchlin C
    Discov Med; 2015 Oct; 20(110):169-75. PubMed ID: 26562469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of psoriatic arthritis.
    Sharma A; Dogra S
    Indian J Dermatol Venereol Leprol; 2010; 76(6):645-51. PubMed ID: 21079307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
    Furue K; Ito T; Furue M
    Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG; Mody E; Husni ME; Qureshi AA
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.